Cassie Yuan

Cassie Yuan asked about VYVGART use in gMG, specifically if patients are receiving the drug using shorter off-cycles than the label due to relapse concerns, and if this trend is consistent with argenx's understanding, potentially acting as a tailwind. She also inquired why triple seronegative gMG patients might not be as responsive.

Answer

Tim Van Hauwermeiren, Chief Executive Officer, confirmed that VYVGART's cyclical dosing is adapted to individual patient needs, as per the label, and that a subset of patients may require more frequent dosing while others need less. He referenced poster data showing an average of 5.2 cycles per year. Luc Truyen, Chief Medical Officer, explained that triple seronegative patients often have a longer diagnostic course and more severe disease, leading to a potentially lower initial signal, but show meaningful benefits in subsequent cycles, consistent with non-seronegatives.

Cassie Yuan from RBC Capital Markets asked about physician practices of using shorter off-cycles for VYVGART in gMG, inquiring if this trend aligns with argenx's understanding and its impact on growth. She also asked Luc Truyen about the reasons for potentially lower initial responsiveness in triple seronegative gMG patients.

Answer

Tim Van Hauwermeiren, Chief Executive Officer, confirmed that VYVGART's label allows for individualized cyclical dosing based on clinical judgment, noting that some patients require more frequent dosing while others need less. Luc Truyen, Chief Medical Officer, hypothesized that triple seronegative patients, often presenting with more severe disease and longer diagnostic courses, may show a lower initial signal due to the need for repair mechanisms, but accrue meaningful benefits in subsequent cycles.